Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 plus pembrolizumab in stage IV non-small cell lung cancer with bone metastases
NL-OMON49669Phase 2Active, not recruiting
- Sponsor
- Bayer Consumer Health
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and radium-223 dichloride in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Bayer Consumer Health. Primary endpoints: Adverse events, Dose-limiting toxicities and 1 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
pembrolizumabradium-223 dichloride
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49669.